Evotec Appoints Rui Wang as Head of Global In Silico and AI
Rhea-AI Summary
Evotec (NASDAQ:EVO) appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI, effective June 2, 2026. He will lead integration of computational science, data and AI across R&D, supporting drug discovery, preclinical development and Just - Evotec Biologics.
Wang previously led Data, Analytics and AI at AstraZeneca and has over 20 years of experience in bioinformatics and AI-enabled drug discovery.
Positive
- Appointment of EVP to lead global in silico and AI efforts
- Over 20 years of data, analytics and AI experience added to leadership
- Background leading Data, Analytics and AI at AstraZeneca
- Role focused on embedding AI across R&D and manufacturing functions
Negative
- None.
News Market Reaction – EVO
In the Jun 2 session, EVO declined 3.91%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous AI Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | AI grant funding | Positive | +1.4% | Gates grant for AI-driven biologics optimization using J.MD™ platform. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Limited AI-tag history: the prior AI-related grant on Jan 8, 2026 saw a modest positive move of 1.38%.
Across AI-tagged history, Evotec has highlighted expanding AI capabilities, notably a Gates Foundation grant on Jan 8, 2026 supporting 10 J.MD™ projects over three years. That news produced a 1.38% gain, suggesting investors reacted constructively to AI-platform funding. Today’s appointment of a Head of Global In Silico and AI continues this emphasis on integrating AI into discovery and development, but with a leadership and organizational focus rather than external funding.
Key Terms
in silico technical
ai technical
r&d technical
bioinformatics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more than 20 years of experience supporting global pharma and biotech organizations to embed scalable data, analytics & AI across R&D, drug development, manufacturing and supply chain functions. In his role, Mr. Wang will spearhead the integration of computational science and data-driven decision-making across the R&D operation, with the goal of creating enterprise-scale solutions that ensure AI and in silico science become key pillars of the Evotec commercial value proposition.
Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:
"Rui will play a key role in our ongoing effort to make Evotec's drug discovery and development enterprise a powerful engine of innovation, integration and operational efficiency. Advanced computational tools are essential to enhancing the value of both our business segments - Drug Discovery and Preclinical Development as well as Just - Evotec Biologics. These tools are not a separate entity but are embedded in everything we do to discover and develop new therapies."
Mr. Wang most recently served as Head of Data, Analytics and AI at AstraZeneca, where he has held roles of increasing responsibility for more than a decade. Prior to that he held positions at European Molecular Biology Laboratory's European Bioinformatics Institute and at Tangram Therapeutics (formerly e-therapeutics). He holds M.Sc. degrees in Bioinformatics from the University of Manchester and in System Design for Internet Applications from Newcastle University.
Rui Wang, Evotec's incoming Head of Global In Silico and AI, added:
"The companies that will lead in AI-enabled drug discovery are those that learn from the right data, generated against the right biological questions, at scale. Evotec is uniquely positioned at the intersection of discovery, data and proprietary platforms. Our focus is to translate this position into a durable scientific advantage by concentrating on the capabilities where we can truly differentiate - scaling them with depth and rigor."
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire